Sugi Holdings Co.,Ltd.
SGIPF • Medical - Pharmaceuticals
$9.49
— 0.00 (0.00%)
EarningsLatest report: Feb 28, 2026
FAVORABLE PROFILEAttractiveConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Solid company profile with reasonable valuation support. The data suggests a balanced quality/value setup.
Market Cap
$1.72B
Growth
143.1%
Cash Flow
4/5
Trend
Mostly stable
Evidence
Positive revenue growth · 271.7%Positive free cash flow · 352.95Consistent free cash flow · 4/5Reasonable earnings multiple · 10.2Manageable debt level · 0.32
Financial data as of: Feb 28, 2026, 12:00 AM UTCLast earnings update: Apr 9, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:36 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$9.50
Change0.00%
Shares Out180.97M
Market Cap$1.72B
52W Range16.29 - 16.29
Beta0.35
P/E5.94
P/S0.26
P/B0.92
P/FCF4.20
EV/Sales0.44
EV/EBITDA6.43
Price$9.50
Change0.00%
Shares Out180.97M
Market Cap$1.72B
52W Range16.29 - 16.29
Beta0.35
P/E5.94
P/S0.26
P/B0.92
P/FCF4.20
EV/Sales0.44
EV/EBITDA6.43
EV/FCF6.93
Earnings Yield16.83%
FCF Yield23.83%
Dividend Yield2.37%
Gross Margin31.79%
Oper. Margin4.81%
Profit Margin4.45%
Debt/Eq0.32
Current Ratio1.34
Quick Ratio0.94
Revenue 5Y143.15%
FCF 5Y156.20%
Volume100.00
Avg Volume50.00
EPS Surprise0.03
Investment DNA
How strong this company looks for long-term investors
76
out of 100
Business Quality
Margins, moat, returns
43/100
Financial Strength
Debt, cash, stability
80/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
93/100
Why this score▼
Positive revenue growth · 271.7%Positive free cash flow · 352.95Consistent free cash flow · 4/5Reasonable earnings multiple · 10.2Manageable debt level · 0.32Healthy liquidity · 1.34
Analyst view
No analyst data available now.
🧾
No insider activity
No recent insider transactions available.